|
 Amgen's drug, romosozumab, met the main goal of showing a
significant difference over Eli Lilly & Co's teriparatide in
improving total hip bone density by the 12th month in postmenopausal
women with osteoporosis.
Osteoporosis is a condition which causes bones to become weak and
brittle leading to an increased risk of fracture.
Osteoporosis can occur in both men and women and at any age, but is
most common in older women, affecting millions of people in the
United States, according to the National Institute of Arthritis and
Musculoskeletal and Skin Diseases.
The study tested the safety, tolerability and efficacy of
romosozumab in women with postmenopausal osteoporosis that had been
previously treated with the commonly used therapy, bisphosphonate.
More than 5 percent of patients on romosozumab experienced adverse
events like common cold, join pain, back pain and headache, Amgen
said on Tuesday.
Romosozumab is being developed with Belgium's UCB SA.
[to top of second column] |
(Reporting By Samantha Kareen Nair in Bengaluru; Editing by Maju
Samuel)
[© 2015 Thomson Reuters. All rights
reserved.] Copyright 2015 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
 |
